Skip to content

Regeneron may be pressed by Sanofi weakness: BMO

July 31, 2017

BMO Capital analyst, Matthew Luchini, reiterated his Market Perform rating on shares of Regeneron Pharma (NASDAQ: REGN) on the belief that REGN could come under pressure following Sanofi’s
2Q results, which saw Dupixent sales of $28.6mn, below consensus ~$30mn and buyside expectations of ~$50mn.

The analyst stated “we believe REGN remains highly sensitive to Dupixent and the miss could cause investors to question the strength of the launch. Thus, we believe management commentary remains key and we will be looking for color on inventory and prescription fill rates/payor dynamics”.

No change to the price target of $484.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: